Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Nasopharyngeal Carcinoma 12Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Neoplasms 1Lymphoma 1Immunotherapy Esophagus Cancer 1Hypopharyngeal Neoplasms 1Hepatic Artery Infusion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

Cisplatin 168Radiotherapy 110pembrolizumab 96Cetuximab 95Docetaxel 74Carboplatin 74Radiotherapy, Intensity-Modulated 55Paclitaxel 51Nivolumab 50Fluorouracil 47Surgical Procedures, Operative 28Radiation 26Magnetic Resonance Spectroscopy 25durvalumab 23Drug Therapy 23Radiosurgery 21Biopsy 19Albumin-Bound Paclitaxel 19130-nm albumin-bound paclitaxel 18Taxes 17tislelizumab 16toripalimab 15Chemoradiotherapy 15Neoadjuvant Therapy 14Erlotinib Hydrochloride 14Blood Specimen Collection 14camrelizumab 13Immunohistochemistry 13Specimen Handling 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Squamous Cell Carcinoma of Head and Neck × nedaplatin × Clear all
NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Beijing Tongren Hospital

Phase 3 Recruiting
272 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05351762 2022-07-05

Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Xijing Hospital

Phase 2 Unknown
55 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡